重组甘精胰岛素注射液对2型糖尿病的疗效与安全性分析

Analysis of Efficacy and Safety of Recombinant Insulin Glargine Injection on Type 2 Diabetes Mellitus

目的分析重组甘精胰岛素注射液对2型糖尿病(T2DM)的疗效与安全性。方法选择罗定市人民医院2018年1月至2021年4月诊治的112例T2DM患者,随机分为试验组和对照组。在基础治疗基础上,56例对照组患者给予口服二甲双胍缓释片治疗,56例试验组患者给予二甲双胍缓释片联合重组甘精胰岛素注射液治疗。比较两组血糖指标、疗效和不良反应率。结果治疗前,两组空腹血糖(FPG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbA1c)比较,差异无统计学意义(P>0.05);治疗3个月或6个月,试验组FPG、2hPG、HbA1c均低于对照组(P<0.05);组内比较,试验组或对照组治疗3个月、6个月的FPG、2hPG、HbA1c均低于治疗前(P<0.05)。试验组疗效优于对照组,总有效率高于对照组(P<0.05)。两组不良反应率比较,差异无统计学意义(P>0.05)。结论重组甘精胰岛素注射液联合二甲双胍缓释片治疗T2DM,疗效优于单独使用二甲双胍缓释片,血糖控制效果更好,安全性较高。

Objective To analyze the efficacy and safety of recombinant insulin glargine injection on type 2 diabetes mellitus(T2DM).Methods The 112 T2DM patients diagnosed and treated in Luoding People’s Hospital from January 2018 to April 2021 were selected and randomly divided into experimental group and control group.On the basis of basic treatment,56 patients in the control group were treated with oral metformin sustained-release tablets,and 56 patients in the experimental group were treated with metformin sustained-release tablets combined with recombinant insulin glargine injection,to compare the blood glucose indicators,curative effect and adverse reaction rate of the two groups.Results Before treatment,there was no significant difference in fasting blood glucose(FPG),2h postprandial blood glucose(2hPG)and glycosylated hemoglobin(HbA1c)between the two groups(P>0.05);treatment for 3 months or 6 months,the experimental group FPG,2hPG,HbA1c lower than the control group(P<0.05);within the group comparison,the FPG,2hPG and HbA1c of the test group or the control group for 3 months and 6 months were lower than before treatment(P<0.05).The therapeutic effect of the experimental group was better than that of the control group,and the total effective rate was higher than that of the control group(P<0.05).There was no significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion Recombinant insulin glargine injection combined with metformin sustained-release tablets in the treatment of T2DM has better efficacy than using metformin sustained-release tablets alone,with better blood sugar control effect and higher safety.